Search Results for: Gastrointestinal Drugs Market to Hit
Gastrointestinal Drugs Market to Hit $48.4 Billion October 6, 2016The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022,...
SOFTGEL FORMULATIONS – Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market August 30, 2016
Ronak Savla, PhD, PharmD, and Jeffrey E. Browne, PhD, indicate formulation screening, development, scale-up, and commercial manufacture of LBDDSs require considerable expertise, and choosing an outsourcing partner with experience and a proven track record is critical.
SPECIAL FEATURE – Improving Bioavailability & Solubility: Chemical & Physical Modification vs. Formulation Development March 4, 2019
Contributor Cindy H. Dubin speaks with several leading companies to explore chemical and physical modification versus formulation development, and new technologies and techniques for improving bioavailability and solubility.
Robert Davidson and Jessica Rousset explain how buccal administration further represents a better alternative to injections or tablets for those patients who have difficulty swallowing.
NON-CANNABIS THERAPY – Cannabinoid Therapy Without Using Cannabis: Direct Effects™ Topical β-Caryophyllene May 1, 2017
Ronald Aung-Din, MD, in view of many documented medical benefits of cannabinoids, but with widely persisting regulations, misinformation, and stigma associated with cannabis, searches for a non-cannabis-derived source of cannabinoid therapy, such as found in β-Caryophyllene.
CAPSULE TECHNOLOGY – Enteric Capsule Drug Delivery Technology – Achieving Protection Without Coating June 2, 2015
Hassan Benameur, PhD, says ECDDT represents a new, faster, and easier means for oral delivery of labile entities, such as peptides, nucleotides, live biopharmaceutical products, and vaccines.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III October 15, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
FORMULATING PEPTIDES – Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides October 15, 2013
Edward T. Maggio, PhD, examines how alkylsaccharides offer exciting prospects for novel formulations, providing non-invasive delivery, stabilization, and immunogenicity reduction for biotherapeutic products, resulting in broader patient acceptance and compliance and an increase in their acceptance as viable commercial pharmaceuticals.
THERAPEUTIC FOCUS: Sufentanil NanoTab Technology: Revolutionizing Patient-Controlled Analgesia March 31, 2013
Pamela P. Palmer, MD, PhD; examines how AcelRx’s system can deliver the benefits of PCA in terms of patient pain relief and satisfaction while reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing the cost burden on the healthcare system.
James Fenton says that while the challenges presented by manufacturing pain management products can be significant for some manufacturers, for the right manufacturer, pain management products can present an ideal opportunity.